Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) SVP Douglas Carr sold 7,043 shares of the company's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $2.55, for a total value of $17,959.65. Following the completion of the sale, the senior vice president owned 507,261 shares in the company, valued at $1,293,515.55. The trade was a 1.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Douglas Carr also recently made the following trade(s):
- On Tuesday, February 3rd, Douglas Carr sold 323 shares of Century Therapeutics stock. The shares were sold at an average price of $1.82, for a total value of $587.86.
Century Therapeutics Trading Up 3.8%
Shares of NASDAQ:IPSC opened at $2.43 on Tuesday. Century Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $3.04. The business has a 50 day moving average of $2.11 and a two-hundred day moving average of $1.13. The company has a market capitalization of $212.38 million, a PE ratio of -17.36 and a beta of 1.70.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.04. Equities research analysts predict that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Century Therapeutics
A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Century Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 456,115 shares of the company's stock valued at $454,000 after purchasing an additional 10,806 shares during the period. Bank of America Corp DE raised its stake in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after purchasing an additional 34,466 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock valued at $86,000 after purchasing an additional 38,052 shares during the last quarter. Prudential Financial Inc. acquired a new position in Century Therapeutics in the 2nd quarter valued at about $25,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Century Therapeutics in the 2nd quarter valued at approximately $38,000. Hedge funds and other institutional investors own 50.20% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently commented on IPSC shares. Zacks Research lowered shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, March 12th. Wall Street Zen upgraded shares of Century Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 7th. TD Cowen initiated coverage on shares of Century Therapeutics in a research note on Wednesday, February 25th. They set a "buy" rating on the stock. Leerink Partners set a $2.00 target price on Century Therapeutics and gave the company a "market perform" rating in a research report on Friday. Finally, Piper Sandler lifted their price target on Century Therapeutics from $2.00 to $4.00 and gave the company an "overweight" rating in a research note on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $3.80.
Get Our Latest Report on IPSC
About Century Therapeutics
(
Get Free Report)
Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.
The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
